Pub. Date : 2006 Oct
PMID : 16504991
12 Functional Relationships(s)Download |
Sentence | Compound Name | Protein Name | Organism |
| 1 | Down regulation of multidrug resistance protein-1 expression in patients with early rheumatoid arthritis exposed to methotrexate as a first disease-modifying antirheumatic drug. | Methotrexate | ATP binding cassette subfamily B member 1 | Homo sapiens |
| 2 | BACKGROUND: Methotrexate (MTX) is the current gold standard conventional disease-modifying antirheumatic drug (DMARD) and is effluxed from cells by several transmembrane proteins, including multidrug resistance protein-1 (MRP1). | Methotrexate | ATP binding cassette subfamily B member 1 | Homo sapiens |
| 3 | BACKGROUND: Methotrexate (MTX) is the current gold standard conventional disease-modifying antirheumatic drug (DMARD) and is effluxed from cells by several transmembrane proteins, including multidrug resistance protein-1 (MRP1). | Methotrexate | ATP binding cassette subfamily B member 1 | Homo sapiens |
| 4 | BACKGROUND: Methotrexate (MTX) is the current gold standard conventional disease-modifying antirheumatic drug (DMARD) and is effluxed from cells by several transmembrane proteins, including multidrug resistance protein-1 (MRP1). | Methotrexate | ATP binding cassette subfamily B member 1 | Homo sapiens |
| 5 | BACKGROUND: Methotrexate (MTX) is the current gold standard conventional disease-modifying antirheumatic drug (DMARD) and is effluxed from cells by several transmembrane proteins, including multidrug resistance protein-1 (MRP1). | Methotrexate | ATP binding cassette subfamily B member 1 | Homo sapiens |
| 6 | AIMS: To compare MRP1 expression in newly diagnosed patients with DMARD-naive rheumatoid arthritis with that in healthy controls and to investigate how MRP1 expression changed after exposure to MTX. | Methotrexate | ATP binding cassette subfamily B member 1 | Homo sapiens |
| 7 | AIMS: To compare MRP1 expression in newly diagnosed patients with DMARD-naive rheumatoid arthritis with that in healthy controls and to investigate how MRP1 expression changed after exposure to MTX. | Methotrexate | ATP binding cassette subfamily B member 1 | Homo sapiens |
| 8 | In patients who were positive for MRP1 at baseline (61%), treatment with MTX and folic acid led to a marked down regulation of MRP1 expression at 6 months. | Methotrexate | ATP binding cassette subfamily B member 1 | Homo sapiens |
| 9 | In patients who were positive for MRP1 at baseline (61%), treatment with MTX and folic acid led to a marked down regulation of MRP1 expression at 6 months. | Methotrexate | ATP binding cassette subfamily B member 1 | Homo sapiens |
| 10 | CONCLUSION: In patients with rheumatoid arthritis expressing MRP1, treatment with MTX and folic acid led to down regulation of MRP1 expression. | Methotrexate | ATP binding cassette subfamily B member 1 | Homo sapiens |
| 11 | CONCLUSION: In patients with rheumatoid arthritis expressing MRP1, treatment with MTX and folic acid led to down regulation of MRP1 expression. | Methotrexate | ATP binding cassette subfamily B member 1 | Homo sapiens |
| 12 | Further studies are required to determine the mechanism behind this observation and whether MRP1 expression mediates altered efficacy to MTX. | Methotrexate | ATP binding cassette subfamily B member 1 | Homo sapiens |